or Try an Advanced Search...

    Technical Analysis for CELU - Celularity Inc.

    Grade Last Price % Change Price Change
    F 2.99 -0.33% -0.01
    CELU closed down 0.33 percent on Wednesday, May 8, 2024, on 17 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 20
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CELU trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -0.33%
    Gapped Up Strength -0.33%
    Oversold Stochastic Weakness -0.33%
    Fell Below 200 DMA Bearish -2.92%
    180 Bearish Setup Bearish Swing Setup -2.92%
    Outside Day Range Expansion -2.92%
    Older End-of-Day Signals for CELU ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 11 hours ago
    Down 1% about 11 hours ago
    60 Minute Opening Range Breakdown about 12 hours ago
    Fell Below Previous Day's Low about 12 hours ago
    10 DMA Resistance about 16 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CELU Chart by TradingView
    Basic chart:

    Profile

    Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
    Classification
    Sector: Industrials
    Industry: Conglomerates
    Keywords: Biotechnology Cancer Biology Immune System Stem Cell Cell Therapy Natural Killer Cell Lymphocytes Therapeutic Solutions

    Is CELU a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 22 Celularity Inc. to Host Investor and Analyst Research & Development Day
    Apr 19 Celularity receives Nasdaq notice regarding late Form 10-K filing
    Apr 19 Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
    Apr 18 Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
    Apr 15 Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
    Apr 8 Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
    Mar 26 Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
    Mar 20 Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
    Mar 14 Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
    Mar 12 Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
    See more CELU news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.9
    52 Week Low 1.59
    Average Volume 77,727
    200-Day Moving Average 3.23
    50-Day Moving Average 4.42
    20-Day Moving Average 3.31
    10-Day Moving Average 3.06
    Average True Range 0.37
    RSI (14) 34.64
    ADX 23.0
    +DI 17.04
    -DI 22.66
    Chandelier Exit (Long, 3 ATRs) 4.52
    Chandelier Exit (Short, 3 ATRs) 4.01
    Upper Bollinger Bands 4.22
    Lower Bollinger Band 2.41
    Percent B (%b) 0.32
    BandWidth 54.77
    MACD Line -0.42
    MACD Signal Line -0.45
    MACD Histogram 0.0283
    Fundamentals Value
    Market Cap 647.05 Million
    Num Shares 216 Million
    EPS -1.03
    Price-to-Earnings (P/E) Ratio -2.90
    Price-to-Sales 6.26
    Price-to-Book 2.86
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.27
    Resistance 3 (R3) 3.28 3.20 3.23
    Resistance 2 (R2) 3.20 3.12 3.19 3.21
    Resistance 1 (R1) 3.09 3.08 3.05 3.08 3.20
    Pivot Point 3.01 3.01 2.98 3.00 3.01
    Support 1 (S1) 2.90 2.93 2.86 2.90 2.78
    Support 2 (S2) 2.82 2.89 2.81 2.77
    Support 3 (S3) 2.71 2.82 2.75
    Support 4 (S4) 2.71